Amazon.com, Inc. 10-Q Summary: Q3 2023
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Amazon.com, Inc. for the period ended September 30, 2023. The company operates three primary segments: North America, International, and Amazon Web Services (AWS). The report reflects a period of significant profitability recovery, driven by cost optimization, increased advertising revenue, and growth in AWS, despite a challenging macroeconomic environment.
Key Financial Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total Net Sales | $143.1 billion | $127.1 billion | $404.8 billion | $364.8 billion |
| Operating Income | $11.2 billion | $2.5 billion | $23.6 billion | $9.5 billion |
| Net Income | $9.9 billion | $2.9 billion | $19.8 billion | $(3.0) billion |
| Diluted EPS | $0.94 | $0.28 | $1.89 | $(0.29) |
| Operating Cash Flow (TTM) | $71.7 billion | $39.7 billion | ||
| Free Cash Flow (TTM) | $21.4 billion | $(19.7) billion | ||
| Cash & Equivalents (End of Period) | $49.6 billion | $53.9 billion | ||
| Long-Term Debt | $61.1 billion | $67.2 billion |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year in Q3 2023. North America sales grew 11%, International sales grew 16%, and AWS sales grew 12%.
- Profitability Surge: Operating income more than quadrupled to $11.2 billion in Q3 2023 compared to $2.5 billion in Q3 2022. This was driven by a turnaround in the North America segment (from a $412M loss to $4.3B income) and reduced losses in the International segment.
- Cost Management: Operating expenses grew at a slower rate than revenue. Sales and marketing expenses decreased 4% year-over-year in Q3, and General and Administrative expenses dropped 16%.
- Segment Performance:
- North America: Turned profitable due to increased unit sales, advertising revenue, and fulfillment efficiencies.
- International: Operating loss narrowed significantly to $95 million from $2.5 billion, aided by advertising growth and FX tailwinds.
- AWS: Operating income increased to $7.0 billion, though growth slowed to 12% due to enterprise customer cost optimization.
- Investments: The company invested $1.25 billion in a convertible note from Anthropic, PBC, and acquired One Medical for approximately $3.5 billion in Q1 2023.
Guidance, Outlook, and Risks
Q4 2023 Guidance:
- Net Sales: Expected between $160.0 billion and $167.0 billion (7% to 12% growth).
- Operating Income: Expected between $7.0 billion and $11.0 billion.
- Assumptions: Guidance assumes no additional business acquisitions, restructurings, or legal settlements.
Management Commentary:
- Management expects macroeconomic factors, including inflation and interest rates, to continue impacting operations.
- AWS growth rates are expected to be impacted by enterprise customer cost optimization efforts.
- Capital expenditures are expected to decrease in 2023, primarily due to lower spending on the fulfillment network.
Risks and Contingencies:
- Legal Proceedings: Significant antitrust litigation is ongoing, including a September 2023 lawsuit by the FTC and state Attorneys General alleging monopolization. Biometric privacy lawsuits are also pending.
- Tax Contingencies: The company faces tax disputes in multiple jurisdictions, including India and Luxembourg, with approximately $5.0 billion in tax contingencies as of September 30, 2023.
- Foreign Exchange: Fluctuations in foreign exchange rates continue to impact reported results, though the impact was favorable in Q3 2023.
Key Facts for Investor Verification
- Free Cash Flow Reversal: Verify the sustainability of the shift from negative free cash flow in the prior year to $21.4 billion positive free cash flow over the trailing twelve months.
- AWS Growth Deceleration: Monitor AWS revenue growth rates (12% in Q3) against historical trends to assess the impact of enterprise cost-cutting.
- Antitrust Exposure: Track the status of the FTC and state antitrust lawsuits, as structural remedies could materially alter business operations.
- One Medical Integration: Assess the financial impact and integration progress of the One Medical acquisition.
- Capital Allocation: Note the cessation of stock repurchases in 2023 (none in the first nine months) despite $6.1 billion remaining in the authorized program.